Compare Immunovant Inc. Common Stock (IMVT) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Johnson & Johnson — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Johnson & Johnson trades at $256.5 (market cap $622.84B). The key difference: Johnson & Johnson is far larger — about 94.1× Immunovant Inc. Common Stock's market cap, and Johnson & Johnson pays a 2.07% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Johnson & Johnson for 129 Days on average.
| IMVT | JNJ | |
|---|---|---|
Market Cap | $6.62B | $622.84B |
Volume | 1,131,364 | 5,277,426 |
Sector | Health | Health |
52-Week High | $44.96 | $278.43 |
52-Week Low | $17.03 | $186.00 |
Typical Hold Time | 0 Days | 129 Days |
Enterprise Value | $5.72B | $651.12B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Johnson & Johnson (JNJ) trades at $256.48, up 0.67% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net income margin and 25.74% ROE, though valuation metrics appear elevated with P/E of 29.98. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales and Q3 earnings anticipation.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and elevated valuation. Analyst consensus targets $286.53 (11.7% upside) with 52.5% buy ratings. Key risks include biosimilar competition for Stelara and debt-to-asset ratio increase to 24.06% in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
